Greenwich Biosciences and its parent company, GW Pharmaceuticals plc, have initiated innovative research programs, pioneering significant advancements in the development of cannabinoid-derived therapies. We've established a proprietary process for manufacturing highly regulated cannabinoid-based pharmaceutical products, ensuring batch-to-batch consistency, stability, and dosage reliability.


Recent Pipeline News


Our company research explores the potential therapeutic applications of cannabinoids across a broad range of disease areas for both orphan and non-orphan indications, with a particular focus on neurological conditions.

For Non-Healthcare Professionals

If you are interested in participating in one of our sponsored clinical trials, please have your physician contact us by clicking here.

For Physicians and/or Sites Interested in Clinical Trials

For physicians, researchers, and institutions interested in conducting external research, visit Medical Information for directions on grant submission.

To learn more about our EPIDIOLEX® (cannabidiol) oral solution clinical trials, please see the website.

For medical inquiries relating to EPIDIOLEX® (cannabidiol) oral solution, contact us by submitting this form